BofA reiterates Sarepta Therapeutics stock Underperform on early trial data

BofA reiterated an Underperform rating with a $19.00 price target on Sarepta (SRPT) versus the current share price of $23.30; the stock has fallen ~76% over the past year. Initial Phase 1/2 single ascending dose data for SRP-1001 (FSHD) and SRP-1003 (DM1) showed dose-dependent muscle exposure, early biomarker effects and favorable tolerability; BofA does not model standalone value for these programs and includes them in a $1B gross pipeline value. Multiple ascending dose data are expected in H2 and registrational studies are targeted to start in 2027, but data disclosure was delayed to early 2026 due to assay validation. Analyst reactions are mixed (Mizuho $31 PT, Jefferies $30, Leerink $15, Wolfe peerperform), signaling idiosyncratic upside/downside risk for SRPT rather than broad market impact.

Analysis

A validated, differentiated muscle delivery platform for oligo/siRNA would be a structural positive not just for the company but for the broader specialty-RNA supply chain: CDMOs and lipid nanoparticle manufacturers would see step function demand and pricing power, while Big Pharma would reassess licensing premiums for delivery-enabled assets. Conversely, incumbent modalities (AAV gene therapy, PMO antisense drugs) face a second-order commercial squeeze in indications where repeat dosing and tissue penetration matter, shifting long-term therapeutic mix and development dollars away from one-shot approaches.

Key risks cluster around execution and credibility rather than pure biology: assay and biomarker validation missteps can trigger outsized re-pricing, and a single delayed or noisy multiple-ascending-dose readout will compress optionality and amplify dilution risk if management needs to fund a registrational pathway. Time horizons separate into near-term (binary data/assay milestones over weeks–months), medium (multiple-dose validation and partner interest across 6–18 months), and long (commercial/regulatory proofs that materially change revenue assumptions over 2–4 years).

From a valuation lens, the upside on a clean, reproducible delivery signal is nonlinear — a cleared regulatory path or strong dose-response could justify a multi-bagger rerating relative to today’s biotech multiples because it converts platform optionality into recurring product economics. That asymmetry argues for option structures that pay off on long-dated, high-impact binary outcomes while keeping cash loss limited if the program disappoints; equally, momentum-driven selling on any further disclosure delays presents a tactical short opportunity ahead of de-risking events.

Key Decisions for Investors

• Directional asymmetric: Buy SRPT Jan 2028 25/55 call spread (long-dated LEAP) financed by selling SRPT 3–6 month calls to fund ~60–80% of premium. Rationale: captures multi-year binary upside if delivery platform validates; max loss = net premium paid, upside ~2–4x if market re-rates on successful data.
• Event-driven hedged equity: Acquire SRPT shares sized as 1–2% of portfolio and buy 6–12 month 30% OTM puts to limit downside; sell 12-month 20–30% OTM calls to finance protection. Rationale: protects against assay/clarity shocks while retaining upside into medium-term regulatory/partnering catalysts; target asymmetric payoff with capped upside ~20–40% and defined downside protection.
• Pair trade to isolate modality risk: Long SRPT Jan 2028 LEAP calls (smaller notional) and short equivalent notional in ALNY or IONS (common-oligo exposure) via 12-month puts to neutralize class moves. Rationale: isolate company-specific delivery upside; profit if platform differentiation is genuine while hedging broader siRNA/share-class rallies.
• Short-term downside: Buy SRPT 3–6 month put spread (e.g., 25%/10% strikes) ahead of any imminent data/assay disclosures; set tight position size and stop if implied volatility collapses after release. Rationale: protects against market disappointment and delay-driven rerate; limited cost with defined max gain if stock re-prices down 30–60%.